A novel small binding protein that targets PCSK9

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Huge advantage with ANGPTL3 inhibitor for HoFH patients with minimal to zero LDLR activity
Huge advantage with ANGPTL3 inhibitor for HoFH patients with minimal to zero LDLR activity
EAS 2020
Huge advantage with ANGPTL3 inhibitor for HoFH patients with minimal to zero LDLR activity
- Prof. Frederick Raal
Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype
Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype
EAS 2020
Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype
- Prof. Frederick Raal